

Haematologica
HAEMATOL/2014/109421
Version 5

The novel β 2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Disclosures: Disclosures: All authors declare to have no conflict of interest.

Contributions: Authorship: CD, MK, AK, HO designed the research, and MK, JB, CA, EW, AM and TaS and ToS performed the re-search, PG, WL, G B, NL, ER, HO contributed proteasome inhibitors and affinity based pro-teasome probes, SH analysed data, CD and AK wrote the paper. All authors state to have no conflicts of interest regarding the contents of this manuscript.